SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (11059)8/9/2018 9:33:44 AM
From: tuck1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (2) of 12215
 
Pieris (PIRS) off some premarket following earnings, as Sanofi and Roche return rights to a couple of early programs. Given how terrible the antibiotics field is, the return of the p. aeruginosa program by Sanofi shouldn't be a huge surprise. The return by Roche is of an I-O program against an undisclosed target. I doubt either event is any indictment of the technology, and other, more mature programs remain on track (though I'm still bearish on the hepcidin program). Given current burn, and allowing for some increase, they have a solid two years of cash. No position at present, but I've been watching, and am tempted to write some puts at this level.

Edit: Wrote some puts just now.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News